To the Editor In an article1 and accompanying editorial2 about intracerebral hemorrhage (ICH) and statins, Flint et al1 and Gonzalez-Castellon and Marshall2 gave too much credence to the controversy about statins causing ICH. Most of this controversy is probably owing to misinterpretation of the results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.3 Flint et al1 slightly misquoted my editorial about this topic,4 suggesting that I attributed the increase in ICH to the high crossover rate in SPARCL. The full quote is below, followed by my comments for clarification.
Spence JD. Statins and Intracerebral Hemorrhage. JAMA Neurol. 2015;72(2):240. doi:10.1001/jamaneurol.2014.4171